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Abstract
It is well established that opioids help the organism to cope with environmental stress, tissue injury, patho-
gen invasion, inflammation, and tumor growth. Opioids elicit immunosupressive effects which may become
benefitial in the context of chronic inflammation, however, it may be detremental in the context of tissue
repair. These direct immunosuppressive effects of opioids would possibly facilitate tumor growth, however,
in the context of pain and distress, which is known to promote tumor progression by a reduction in NK cell
cytotoxicity, opioids clearly show a beneficial effect in reducing local tumor growth as well as dissemination
of metastases. Recently, growing evidence accumulates that tumor cells express both opioid receptors and
their ligands, the opioid peptides, suggesting that opioids may also directly affect tumor progression. Met-
enkephalin seems to play a most prominent role possibly acting via a different receptor than the classical
opioid receptor. However, there is still great need for further studies to corroborate these interesting
findings.
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Introduction
Cancer patients are often treated with high dos-
es of opioids such as morphine for pain relief. Opio-
id analgesics act on their corresponding receptors,
mainly m-opioid receptors, along the neuraxis of pain
transmission, i.e. peripheral sensory neurons, spinal
cord, and brain [1]. They inhibit the release of exci-
tatory neurotransmitters and reduce the excitability
of sensory neurons which results in subsequent pain
relief. The opioid system consisting of opioid recep-
tors and endogenous opioid ligands exists in verte-
brates since more than 400–500 million years [2, 3].
Therefore, it is conceivable that opioids do not only
modulate pain, but also affect many other physio-
logical functions. Indeed opioid receptors also exist
outside the nervous system [4], and previous stud-
ies have emphasized the role of opioids to cope
with environmental stress (i.e. mechanical, thermal,
chemical), tissue injury, pathogen invasion, inflam-
mation, and tumor growth [1]. This review will fo-
cus on the immunemodulatory effects of opioids
and in particular their impact on tumor growth and
dissemination of metastases.
Opioid effects on the immune system
The discussion about the influence of opioids on
the immune system is not new. Already in the 1980s
many in vitro studies were published with contro-
versial results [for review see 5]. However, more re-
cent results from opioid receptor knock-out mice
strongly support an immunosuppressive effect. Con-
sistently, chronic use of opioids has been associat-
ed with an increased incidence of infectious diseas-
es such as HIV or tuberculosis [6–8]. Early reports by
Liebeskind and colleagues demonstrated immuno-
supressive effects of morphine that were depen-
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dent on activation of central opioid receptors and
of the hypothalamo-pituitary stress axis [9]. The
periaqueductal grey area has been identified as a
brain region with a high density of opioid receptors
that reliably respond with immunosuppression fol-
lowing injections of opioids [10]. However, opioids
also exert their immunosuppressive effects via opi-
oid receptors on various immune cells such as gran-
ulocytes, monocytes/macrophages and lymphocytes.
All opioid receptors (m-, d-, k) are present on im-
mune cells, they couple to Gai/o proteins and they
influence immune cell function [11, 12]. In addi-
tion, all opioid peptides — b-endorphin, enkephalin
and dynorphin — their precursors, and necessary
processing enzymes were identified in activated
granulocytes, monocytes and lymphocytes suggest-
ing an autoregulatory role [13]. Immunosuppres-
sive effects are more overt following chronic opioid
administration resulting in atrophy of thymus and
spleen and inhibition of NK cell activity [14]. Consis-
tently, m-receptor knock-out compared to wild type
mice lacked lymphoid organ (thymus, spleen) atro-
phy as well as inhibition of NK cell activity [15]. In a
very impressive example of the immunosuppressive
effects of opioids it was demonstrated that m- and
d-opioid agonists resulted in a dramatic reduction
of macroscopic and microscopic inflammatory signs,
an almost complete reversal of immune cell infiltra-
tion, and more importantly a significant reduction
in mortality [16]. These effects are in part due to
local opioid effects on immune cells as it has been
shown with the use of peripherally selective opioids
that profoundly diminish macroscopic and micro-
scopic signs of arthritis [17, 18]. Whether immuno-
suppressive effects of opioids are to the advantage
or disadvantage of the organism, is very much de-
pendent on the situation under which opioids and
the immune system interact [19]. For example in
arthritis and autoimmune disease an immunosup-
pressive effect of opioids is advantageous, whereas
in conditions such as HIV and drug addiction immu-
nosuppressive effects of opioids might lead to fur-
ther complications such as infections and disturbed
wound healing [20].
Opioids, natural killer cells and tumor
progression
Studies showing direct effects of exogenous opi-
oids on tumor growth and dissemination are still
contradictory, because experiments were mainly
done in cell cultures under in vitro conditions. While
it is reported that morphine stimulates microvascu-
lar endothelial-cell proliferation and angiogenesis
in breast cancer cells [21], it is also described that
morphine inhibits the adhesion, invasion and me-
tastases of colon cancer cells [22]. However, to look
exclusively at direct effects of opioids on tumor cells
may not comply with the much more complex sce-
nario of tumor progression in cancer patients.
Tumor progression is — particularly through its
initial stage — under immune surveillance. Trans-
formed surface antigen presenting cancer cells may
become a target for cytotoxic natural killer (NK) cells.
This initiates an ”evolutionary” process of selection
pressure by the immune system upon malignant
cells [23]. Some tumors seem to be more suscepti-
ble to cytotoxic NK cell activity, e.g. melanomas and
breast cancer, whereas others are less, e.g. colon
cancer. Pain and subsequent stress, e.g. following
surgery, have been shown to signicantly impair NK
cell activity which led to enhanced lung tumor re-
tention of mammary adenocarcinoma cells in ani-
mals [24]. In NK cell depleted animals, however,
this enhanced lung tumor retention could not be
observed underlining the important involvement of
cytotoxic NK cells. Consistently, NK cell number and
activity of patients undergoing major surgery were
significantly reduced [25]. In patients with hepato-
cellular or gastric carcinoma, impaired NK cell activ-
ity following surgery was demonstrated to be a prog-
nostic predictor for increased tumor progression and
dissemination [26, 27]. Although several studies in
healthy animals have shown that opioids suppress
NK cell activity [28], in the context of surgery, pain,
and distress opioids rescued impaired NK cell activ-
ity [24, 29]. This resulted in significantly reduced
tumor dissemination and increased survival [24, 30].
In a very elegant animal study of melanoma cells
inoculated in the paw of mice, time-dependent lo-
cal tumor growth and dissemination of lung me-
tastases were dose-dependently reduced by increas-
ing doses of morphine which was naloxone revers-
ible [31]. Therefore, similar to the immunosuppres-
sive effects of opioids which may be advantageous
in the context of chronic arthritis and disadvanta-
geous in the context of wound healing, opioids in
the absence or presence of pain may impair or res-
cue NK cell activity and limit tumor progression,
respectively.
Expression of opioid receptors
and peptides in tumor tissue
Recently evidence is accumulating that different
tumor cells express opioid receptors and their en-
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dogenous ligands, the opioid peptides. In a human
colon cancer cell line as well as in tumor tissue of
human colon cancer patients mu-opioid receptors
were identified by immunohistochemistry suggest-
ing that opioids may affect tumor progression [32].
In addition, opioid peptides (mainly b-endorphin
and Met-enkephalin) and their precursors have been
demonstrated in breast cancer cell lines and in tu-
mor tissue of the majority of human breast cancer
patients [33, 34]. Evidence for b-endorphin and opi-
oid receptor binding sites have also been demon-
strated in human lung cancer cell lines [35, 36]. In a
systematic screening of different opioid peptides
for their inhibitory effects on the proliferation of a
murine neuroblastoma cell line Met-enkephalin was
identified to be the most potent opioid peptide
[37]. Interestingly in this screening assay, prodynor-
phin- and proopiomelanocortin-derived peptides did
not have a significant influence on cultured cells.
Therefore, it was postulated that not the traditional
opioid receptors but a new, yet unidentified recep-
tor was responsible for the antiproliferative proper-
ties [37]. This receptor has been cloned and se-
quenced in human, rat, and mouse and presumably
has no resemblance to the classical opioid receptors
or other known receptors [37]. Because of Met-en-
kephalin's newly discovered properties different from
its analgesic effects, it was named “opioid growth
factor” (OGF) and its receptor “opioid growth fac-
tor receptor”. Recently, OGF receptor has been iden-
tified in several human cancer tissues [38, 39] and
patients with advanced unresectable pancreatic can-
cer have been treated with OGF without major com-
plications in a first phase I clinical trial [40]. Al-
though these results look very promising, they have
to be confirmed by other groups. Taken together,
cancer cells seem to express both opioid receptors
and their endogenous ligands to regulate tumor
proliferation most likely by an autocrine mechanism.
Summary
Consistent with its existence in vertebrates since
more than 500 million years, opioids help the or-
ganism to cope with environmental stress, tissue
injury, pathogen invasion, inflammation, and tu-
mor growth. There is clear evidence for an immuno-
supressive effect of opioids which may be benefitial
in chronic inflammatory conditions, however, it may
be detremental in conditions such as tissue repair.
This immunosuppressive effect of opioids would
possibly facilitate tumor growth, however, in the
context of pain and distress, which promote tumor
progression by a reduction in NK cell cytotoxicity,
opioids clearly show a beneficial effect in reducing
local tumor growth as well as dissemination of me-
tastases. Recently, evidence is accumulating that
tumor cells express both opioid receptors and opio-
id peptides, their endogenous ligands, suggesting
that opioids may affect tumor progression. Met-
enkephalin seems to play an important role possi-
bly acting via a different receptor than the classical
opioid receptor. However, future studies have to
corroborate these promising findings.
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